Canlyniadau Chwilio - Popat, Rakesh

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case seri... gan Popat, Rakesh, Warcel, Dana, O’Nions, Jenny, Cowley, Anna, Smith, Sasha, Tucker, William R, Yong, Kwee, Esposti, Simona Degli

Cael y testun llawn Cael y testun llawn Cael y testun llawn

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma gan Prawitz, Thibaud, Popat, Rakesh, Suvannasankha, Attaya, Sarri, Grammati, Hughes, Rachel, Wang, Feng, Hogea, Cosmina, Ferrante, Shannon Allen, Gorsh, Boris, Willson, Jenny, Kapetanakis, Venediktos

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response gan Latifoltojar, Arash, Hall‐Craggs, Margaret, Rabin, Neil, Popat, Rakesh, Bainbridge, Alan, Dikaios, Nikolaos, Sokolska, Magdalena, Rismani, Ali, D'Sa, Shirley, Punwani, Shonit, Yong, Kwee

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase I trial of talazoparib in patients with advanced hematologic malignancies gan Gopal, Ajay K, Popat, Rakesh, Mattison, Ryan J, Menne, Tobias, Bloor, Adrian, Gaymes, Terry, Khwaja, Asim, Juckett, Mark, Chen, Ying, Cotter, Matthew J, Mufti, Ghulam J

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Deferred autologous stem cell transplantation in systemic AL amyloidosis gan Manwani, Richa, Hegenbart, Ute, Mahmood, Shameem, Sachchithanantham, Sajitha, Kyriakou, Charalampia, Yong, Kwee, Popat, Rakesh, Rabin, Neil, Whelan, Carol, Dittrich, Tobias, Kimmich, Christoph, Hawkins, Philip, Schönland, Stefan, Wechalekar, Ashutosh

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study gan Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induc... gan Latifoltojar, Arash, Hall-Craggs, Margaret, Bainbridge, Alan, Rabin, Neil, Popat, Rakesh, Rismani, Ali, D’Sa, Shirley, Dikaios, Nikolaos, Sokolska, Magdalena, Antonelli, Michela, Ourselin, Sebastien, Yong, Kwee, Taylor, Stuart A., Halligan, Steve, Punwani, Shonit

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiv... gan Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma gan Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh

Cael y testun llawn Cael y testun llawn Cael y testun llawn

COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial gan Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, Yong, Kwee

Cael y testun llawn Cael y testun llawn Cael y testun llawn

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia gan Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio, Cecilia, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch, Francesc, Somervaille, Tim C. P.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study gan Camilleri, Marquita, Bekris, Georgios, Sidhu, Govundeep, Buck, Caroline, Elsden, Esma, McCourt, Orla, Horder, Jackie, Newrick, Fiona, Lecat, Catherine, Sive, Jonathan, Papanikolaou, Xenofon, Popat, Rakesh, Lee, Lydia, Xu, Ke, Kyriakou, Charalampia, Rabin, Neil, Yong, Kwee, Fisher, Abigail

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy gan Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modifie... gan Koutoukidis, Dimitrios A., Land, Joanne, Hackshaw, Allan, Heinrich, Malgorzata, McCourt, Orla, Beeken, Rebecca J., Philpott, Stephanie, DeSilva, Dunnya, Rismani, Ali, Rabin, Neil, Popat, Rakesh, Kyriakou, Charalampia, Papanikolaou, Xenofon, Mehta, Atul, Paton, Bruce, Fisher, Abigail, Yong, Kwee L.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma gan Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A., Laubach, Jacob, Gasparetto, Cristina, Chanan-Khan, Asher, Hertzberg, Mark, deMario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay

Cael y testun llawn Cael y testun llawn Cael y testun llawn

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma gan Morris, Treen Carson Michael, Drake, Mary B., Kettle, Paul J., McGuigan, Tracey, Leahy, Maeve, O’Dwyer, Michael, Enright, Helen, O’Shea, Tanya, Popat, Rakesh, Oakervee, Heather E., Yong, Kwee, Cavenagh, Jamie D., Cairns, David A., Alvarez-Iglesias, Alberto, Cook, Gordon

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159) gan Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Anderson, Larry D., Sutherland, Heather J., Yong, Kwee, Hoos, Axel, Gorczyca, Michele M., Lahiri, Soumi, He, Zangdong, Austin, Daren J., Opalinska, Joanna B., Cohen, Adam D.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study gan Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study gan Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn

Cael y testun llawn Cael y testun llawn Cael y testun llawn

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma gan Bruno, Benedetto, Wäsch, Ralph, Engelhardt, Monika, Gay, Francesca, Giaccone, Luisa, D’Agostino, Mattia, Rodríguez-Lobato, Luis-Gerardo, Danhof, Sophia, Gagelmann, Nico, Kröger, Nicolaus, Popat, Rakesh, van de Donk, Niels W C J, Terpos, Evangelos, Dimopoulos, Meletios A, Sonneveld, Pieter, Einsele, Hermann, Boccadoro, Mario

Cael y testun llawn Cael y testun llawn Cael y testun llawn